Dificid approval promises CDAD market shake-up
This article was originally published in Scrip
Executive Summary
On 27 May, the US Food and Drug Administration (FDA) approved San Diego-based Optimer Pharmaceuticals' Dificid (fidaxomicin), a new antibiotic for the treatment of Clostridium difficile-associated diarrhoea (CDAD).